1. Homepagina
  2. Aandelen
  3. Zweden
  4. NORDIC GROWTH MARKET
  5. EQL Pharma AB (publ)
  6. Nieuws
  7. Persberichten
    EQL   SE0005497732

EQL PHARMA AB (PUBL)

(EQL)
  Rapport
slotkoers NORDIC GROWTH MARKET  -  11-08-2022
31.60 SEK   -0.32%
13/05EQL Pharma AB (publ) Rapporteert Winstresultaten voor het Vierde Kwartaal en het Hele Jaar Eindigend op 31 Maart, 2022
CI
11/05EQL Pharma verleent uitlicentie voor Mellozzan aan H.A.C. Pharma in ADHD
CI
05/05EQL Pharma ontvangt goedkeuring voor Glycopyrronium EQL Pharma Oplossing voor Injectie 0,2Mg/Ml van Deens Geneesmiddelenbureau
CI
OverzichtKoersenGrafiekenNieuwsAgendaOndernemingFinanciŽn 
OverzichtAl het nieuwsAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť EQL PHARMA AB (PUBL)
11/07Invitation to presentation in connection with EQL Pharma's quarterly report, first quar..
AQ
08/07EQL PHARMA : Instruction for the Nomination Committee
PU
08/07EQL PHARMA : Notice of annual general meeting on 17 August 2022
PU
08/07Notice of annual general meeting in EQL Pharma AB
AQ
13/05Year-end Report April 2021 - March 2022
AQ
11/05EQL Pharma out-license Mellozzan to a leading French Company in ADHD
AQ
05/05EQL Pharma get Glycopyrronium EQL Pharma approved
AQ
26/04Invitation to presentation in connection with EQL Pharma's year-end report, fourth quar..
AQ
22/03EQL Pharma out-license Mellozzan to a leading European Company in ADHD
AQ
04/03EQL Pharma's melatonin tablets approved in Denmark and Norway
AQ
03/03EQL Pharma donates 2500 bottles of Hevicain (bupivacaine) to Ukraine
AQ
16/02EQL PHARMA : Nterim report April-September 2021
PU
16/02Interim Report April - December 2021
AQ
28/01Invitation to presentation in connection with EQL Pharma's quarterly report, third quar..
AQ
13/01EQL Pharma AB preliminarily announces very strong outcome for the third quarter and rep..
AQ
2021EQL Pharma receives SEK 23 million order for covid self-test
AQ
2021EQL Pharma appoints permanent CFO
AQ
2021Bulletin from the extraordinary general meeting in EQL Pharma AB on 10 December 2021
AQ
2021Notice of extraordinary general meeting in EQL Pharma AB
AQ
2021EQL Pharma will change CEO during 2022
AQ
2021Interim Report April - September 2021
AQ
2021EQL PHARMA : Invitation to presentation in connection with EQL Pharma's quarterly report, ..
AQ
2021EQL PHARMA : Latanoprost EQL Pharma Approved
AQ
2021EQL PHARMA : to exclusively launch first CE marked saliva based Covid-19 antigen self-test
AQ
2021EQL PHARMA : Ondansetron EQL Pharma Approved
AQ
2021EQL PHARMA : Bulletin from the annual general meeting in EQL Pharma AB on 17 August 2021
AQ
2021EQL PHARMA : Interim Report April - June 2021
AQ
2021EQL PHARMA : takes back Potassium Chloride rights in Denmark and Norway
AQ
2021EQL PHARMA : Annual Report 2020/2021
AQ
2021EQL PHARMA : Invitation to presentation in connection with EQL Pharma's quarterly report, ..
AQ
2021EQL PHARMA : Notice of annual general meeting in EQL Pharma AB
AQ
2021EQL PHARMA : Mellozzan (melatonin) is now Reimbursed
AQ
2021EQL PHARMA : nbsp;Year-end Report April 2020 - March 2021
AQ
2021EQL PHARMA : distributes Europe's first CE marked SARS-CoV-2 self-test
AQ
2021EQL PHARMA : Invitation to presentation in connection with EQL Pharma's quarterly report, ..
AQ
2021EQL PHARMA : Colecalciferol EQL Pharma Approval
AQ
2021EQL PHARMA : chooses to postpone the list change to Nasdaq Stockholm
AQ
2021EQL PHARMA : CFO has chosen to leave her position
AQ
2021EQL PHARMA : becomes Nordic representative for Qilu Pharmaceuticals
AQ
Volgende evenement op EQL PHARMA AB (PUBL)